These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30388368)

  • 1. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
    Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
    J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility.
    Zak M; Liederer BM; Sampath D; Yuen PW; Bair KW; Baumeister T; Buckmelter AJ; Clodfelter KH; Cheng E; Crocker L; Fu B; Han B; Li G; Ho YC; Lin J; Liu X; Ly J; O'Brien T; Reynolds DJ; Skelton N; Smith CC; Tay S; Wang W; Wang Z; Xiao Y; Zhang L; Zhao G; Zheng X; Dragovich PS
    Bioorg Med Chem Lett; 2015 Feb; 25(3):529-41. PubMed ID: 25556090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
    Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
    Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
    Sevrioukova IF; Poulos TL
    Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.
    Tang LWT; Teng JW; Koh SK; Zhou L; Go ML; Chan ECY
    Chem Res Toxicol; 2021 Jul; 34(7):1800-1813. PubMed ID: 34189909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4.
    Guo X; Li W; Li Q; Chen Y; Zhao G; Peng Y; Zheng J
    Chem Res Toxicol; 2019 Sep; 32(9):1791-1800. PubMed ID: 31414593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
    Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
    Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
    Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
    Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amelioration of mechanism-based inactivation of CYP3A4 by a H-PGDS inhibitor.
    Vaz RJ; Li Y; Munson M; Elliot M; Thurairatnam S
    Bioorg Med Chem Lett; 2018 Oct; 28(18):3046-3049. PubMed ID: 30115511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
    Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
    Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.
    Guengerich FP; McCarty KD; Chapman JG
    J Biol Chem; 2021; 296():100223. PubMed ID: 33449875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of In Silico Models for Predicting Potential Time-Dependent Inhibitors of Cytochrome P450 3A4.
    Xu M; Lu Z; Wu Z; Gui M; Liu G; Tang Y; Li W
    Mol Pharm; 2023 Jan; 20(1):194-205. PubMed ID: 36458739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infigratinib Is a Reversible Inhibitor and Mechanism-Based Inactivator of Cytochrome P450 3A4.
    Tang LWT; Teng JW; Verma RK; Koh SK; Zhou L; Go ML; Fan H; Chan ECY
    Drug Metab Dispos; 2021 Sep; 49(9):856-868. PubMed ID: 34326139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.
    Jennings GK; Ritchie CM; Shock LS; Lyons CE; Hackett JC
    Mol Pharmacol; 2016 Jul; 90(1):42-51. PubMed ID: 27126611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition.
    Zientek M; Stoner C; Ayscue R; Klug-McLeod J; Jiang Y; West M; Collins C; Ekins S
    Chem Res Toxicol; 2010 Mar; 23(3):664-76. PubMed ID: 20151638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
    Nembri S; Grisoni F; Consonni V; Todeschini R
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of Spin-Labelled Bergamottin: A Potent CYP3A4 Inhibitor with Antiproliferative Activity.
    Zsidó BZ; Balog M; Erős N; Poór M; Mohos V; Fliszár-Nyúl E; Hetényi C; Nagane M; Hideg K; Kálai T; Bognár B
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31941150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 2,4-diamino-5-cyanopyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions.
    Kunikawa S; Tanaka A; Takasuna Y; Tasaki M; Chida N
    Bioorg Med Chem; 2019 Mar; 27(5):790-799. PubMed ID: 30704835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.